Star Therapeutics Reports Positive Phase 1/2 Data for VGA039 in von Willebrand Disease at ASH 2025
核心洞察
Star Therapeutics (搜索) will present interim data from its Phase 1/2 multidose study of VGA039, showing the novel Protein S-targeting monoclonal antibody is well-tolerated and substantially reduces bleeding rates in von Willebrand disease (搜索) patients.
VGA039 offers a convenient subcutaneous, once-monthly dosing regimen that could dramatically reduce treatment burden compared to current therapies requiring multiple weekly intravenous infusions.
The therapy has received FDA Fast Track and orphan drug designations and has advanced to Phase 3 trials, positioning it as a potential universal hemostatic therapy for multiple bleeding disorders.
Star Therapeutics (搜索) announced it will present promising interim data from its Phase 1/2 multidose study of VGA039 for von Willebrand disease (搜索) (VWD) at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025. The oral presentation, titled "Subcutaneous, Every-Four-Week Maintenance Dosing of a Novel Protein S Antibody is Well-Tolerated and Substantially Reduces Bleeding Rates," demonstrates the potential of this first-in-class monoclonal antibody therapy.
Novel Mechanism Targets Protein S
VGA039 represents a breakthrough approach to treating bleeding disorders through its novel mechanism of action that targets Protein S, thereby restoring balance to the blood clotting process. This first-in-class monoclonal antibody therapy has the potential to serve as a universal hemostatic treatment for numerous bleeding disorders, beginning with VWD.
The therapy's subcutaneous, self-administered format with convenient once-monthly dosing could dramatically reduce treatment burden for patients. This represents a significant advancement over current VWD prophylaxis therapies, which require multiple intravenous infusions every week.
Regulatory Recognition and Clinical Progress
VGA039 has received both Fast Track and orphan drug designations from the United States Food and Drug Administration (FDA), highlighting its potential to address significant unmet medical needs. The therapy builds on positive interim data from a Phase 1 single ascending dose study previously reported at ASH in December 2024.
The ongoing Phase 1/2 multidose study (NCT05776069) has now advanced to Phase 3 development. The Phase 3 study (NCT07115004) is designed as a global single arm cross-over study investigating the safety and efficacy of subcutaneous VGA039 administration as prophylaxis for bleeding in patients with every type of VWD.
Comprehensive ASH Presentation Program
Beyond the primary oral presentation by Dr. Allison Wheeler on December 6, 2025, Star Therapeutics (搜索) will present three additional posters exploring various aspects of VGA039's therapeutic potential. These include the first characterization of disease burden for severe VWD using real-world U.S. data, presented by Dr. Angela Weyand, and preclinical studies demonstrating VGA039's efficacy across multiple bleeding disorders including hemophilia A (搜索), B, and C.
Addressing Significant Unmet Need
Von Willebrand disease (搜索) affects more than 130,000 people in the United States, making it the most common inherited bleeding disorder. The condition results from absent or defective von Willebrand factor (VWF), causing blood clotting dysfunction that leads to excessive bleeding with variable severity and frequency, significantly impacting patients' daily lives.
Star Therapeutics (搜索), based in South San Francisco, has established expertise in novel antibody development, with its leadership team having previously invented four first-in-class antibodies, including ENJAYMO®, the first approved drug for cold agglutinin disease (搜索). The company has raised more than $300 million from leading life sciences investors to support its mission of creating life-changing therapies for patients with unmet needs in hematology and immunology.